Clinical Trial: TRAQinform Assessment of Immunotherapy Response
Study Status: Completed
Recruit Status: RECRUITING
Condition: Melanoma
Study Type: OBSERVATIONAL
Official Title: Comprehensive Assessment of Cancer Immunotherapy Response; Investigating the Intent to Change Treatment Decisions Based Upon TRAQinform Immuno Technology
Brief Summary:
The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study.Subjects with metastatic melanoma treated with standard of care (SOC) dual-agent immunotherapy will be enrolled.Subjects will receive SOC immunotherapy monitored for treatment response with FDG PET/CT's at baseline (SOC), after 3-4 weeks of treatment (non-SOC) and 12 at weeks of treatment (SOC).
Read more